Abstract
Aim:
To examine the effects of β3-adrenoceptor (β3-AR) activation on atherosclerotic plaque development in ApoE−/− mice.
Methods:
Thirty six week-old male ApoE−/− mice on a high-fat diet were treated with atorvastatin (10 mg·kg-1·d-1, po), BRL37344 (β3-AR agonist, 1.65 or 3.30 μg/kg, ip, twice a week) or SR52390A (β3-AR antagonist, 50 μg/kg, ip, twice a week) for 12 weeks. Wild-type C57BL/6J mice receiving a normal diet were taken as healthy controls. At the end of the treatments, serum levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-high density lipoprotein cholesterol (nHDL-C), glucose and insulin were measured. The thoracic aortas were dissected out, the area of atherosclerotic plaques and extent of fibrosis in the plaques were examined using HE and Masson's trichome staining, respectively.
Results:
Compared to wild-type mice, ApoE−/− mice fed on a high-fat diet exhibited prominent hyperlipidemia and insulin resistance, associated with large area of atherosclerotic plaques and great extent of fibrosis in aortas. Atorvastatin significantly decreased the serum levels of TC and nHDL-C, and reduced the plaque area and collagen content in aortas. BRL37344 significantly decreased the serum levels of TG, TC, nHDL-C, glucose and insulin, and increased HDL-C and the insulin sensitivity, and dose-dependently reduced the plaque area and collagen content in aortas. SR52390A treatment did not affect any parameters studied.
Conclusion:
The β3-AR agonist impedes the progression of atherosclerosis in ApoE−/− mice, through improvement of the lipid and glucose profiles.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Tan S, Curtis-Prior PB . Characterization of the beta-adrenoceptor of the adipose cell of the rat. Int J Obes 1983; 7: 409–14.
Grujic D, Susulic VS, Harper ME, Himms-Hagen J, Cunningham BA, Corkey BE, et al. Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J Biol Chem 1997; 272: 17686–93.
Chernogubova E, Cannon B, Bengtsson T . Norepinephrine increases glucose transport in brown adipocytes via beta3-adrenoceptors through a cAMP, PKA, and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinology 2004; 145: 269–80.
Collins S, Daniel KW, Rohlfs EM, Ramkumar V, Taylor IL, Gettys TW . Impaired expression and functional activity of the beta 3- and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. Mol Endocrinol 1994; 8: 518–27.
Kato H, Ohue M, Kato K, Nomura A, Toyosawa K, Furutani Y, et al. Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model. Diabetes 2001; 50: 113–22.
Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y . The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor–alpha expressions in adipose tissues of obese diabetic KKAy mice. Eur J Pharmacol 2008; 584: 202–6.
Kim H, Pennisi PA, Gavrilova O, Pack S, Jou W, Setser-Portas J, et al. Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice. Am J Physiol Endocrinol Metab 2006; 290: E1227–36.
Corella D, Ordovas JM . The metabolic syndrome: a crossroad for genotype-phenotype associations in atherosclerosis. Curr Atheroscler Rep 2004; 6: 186–96.
Zhang SH, Reddick RL, Piedrahita JA, Maeda N . Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468–71.
Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005; 111: 1422–30.
Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C . Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 183–9.
Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA . Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68: 231–40.
Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y . Beta-adrenoceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 and tumor necrosis factor-alpha expression in adipocytes. Eur J Pharmacol 2007; 569: 155–62.
Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402–8.
Kawashima Y, Chen J, Sun H, Lann D, Hajjar RJ, Yakar S, et al. Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Diabetologia 2009; 52: 1434–41.
Tamminen M, Mottino G, Qiao JH, Breslow JL, Frank JS . Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 847–53.
Tanaka A . Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb 2004; 11: 322–9.
Carneiro AV, Costa J, Borges M . Statins for primary and secondary prevention of coronary heart disease. A scientific review. Rev Port Cardiol 2004; 23: 95–122.
Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C . Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1755–60.
Assmann G, Schulte H, von Eckardstein A, Huang Y . High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11–20.
Quinn R . Comparing rat's to human's age: how old is my rat in people years? Nutrition 2005; 21: 775–7.
Jawień J, Nastałek P, Korbut R . Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503–17.
Kypreos KE, Karagiannides I, Fotiadou EH, Karavia EA, Brinkmeier MS, Giakoumi SM, et al. Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J 2009; 276: 5720–8.
Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L . Central administration of oleic acid inhibits glucose production and food intake. Diabetes 2002; 51: 271–5.
Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706–21.
Margareto J, Larrarte E, Marti A, Martinez JA . Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist. Biochem Pharmacol 2001; 61: 1471–8.
Tchivileva IE, Tan KS, Gambarian M, Nackley AG, Medvedev AV, Romanov S, et al. Signaling pathways mediating beta3-adrenergic receptor-induced production of interleukin-6 in adipocytes. Mol Immunol 2009; 46: 2256–66.
Granneman JG, Burnazi M, Zhu Z, Schwamb LA . White adipose tissue contributes to UCP1-independent thermogenesis. Am J Physiol Endocrinol Metab 2003; 285: E1230–6.
Cao W, Medvedev AV, Daniel KW, Collins S . Beta-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase. J Biol Chem 2001; 276: 27077–82.
Mottillo EP, Shen XJ, Granneman JG . Role of hormone-sensitive lipase in beta-adrenergic remodeling of white adipose tissue. Am J Physiol Endocrinol Metab 2007; 293: E1188–97.
Robidoux J, Kumar N, Daniel KW, Moukdar F, Cyr M, Medvedev AV, et al. Maximal beta3-adrenergic regulation of lipolysis involves Src and epidermal growth factor receptor-dependent ERK1/2 activation. J Biol Chem 2006; 281: 37794–802.
Kolovou GD, Anagnostopoulou KK, Cokkinos DV . Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005; 81: 358–66.
Oana F, Takeda H, Matsuzawa A, Akahane S, Isaji M, Akahane M . Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist. Eur J Pharmacol 2005; 518: 71–6.
Coman OA, Păunescu H, Ghiţă I, Coman L, Bădărăru A, Fulga I . Beta 3 adrenergic receptors: molecular, histological, functional and pharmacological approaches. Rom J Morphol Embryol 2009; 50: 169–79.
Suzuki M, Kakuta H, Takahashi A, Shimano H, Tada-Iida K, Yokoo T, et al. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J Atheroscler Thromb 2005; 12: 77–84.
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T . Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–92.
Gettys TW, Watson PM, Seger L, Padgett M, Taylor IL . Adrenalectomy after weaning restores beta3-adrenergic receptor expression in white adipocytes from C57BL/6J-ob/ob mice. Endocrinology 1997; 138: 2697–704.
Fève B, Elhadri K, Quignard-Boulangé A, Pairault J . Transcriptional down-regulation by insulin of the beta 3-adrenergic receptor expression in 3T3-F442A adipocytes: a mechanism for repressing the cAMP signaling pathway. Proc Natl Acad Sci U S A 1994; 91: 5677–81.
Baranowski M . Biological role of liver X receptors. J Physiol Pharmacol 2008; 59: 31–55.
Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007; 581: 5029–33.
Wang H, Peng DQ . New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis 2011; 10: 176.
Capurso C, Capurso A . From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol 2012; 57: 91–7.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (Grant No 81270380).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Zh., Li, Yf. & Guo, Yq. β3-Adrenoceptor activation attenuates atherosclerotic plaque formation in ApoE−/− mice through lowering blood lipids and glucose. Acta Pharmacol Sin 34, 1156–1163 (2013). https://doi.org/10.1038/aps.2013.70
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2013.70
Keywords
This article is cited by
-
Brown adipose tissue and its therapeutic application
Science Bulletin (2016)
